Brokerages Expect Athersys, Inc. (NASDAQ:ATHX) to Post ($0.08) Earnings Per Share
Shares of Athersys, Inc. (NASDAQ:ATHX) have earned a consensus broker rating score of 1.00 (Strong Buy) from the one analysts that provide coverage for the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a strong buy rating.
Brokers have set a twelve-month consensus target price of $11.00 for the company and are forecasting that the company will post ($0.08) EPS for the current quarter, according to Zacks. Zacks has also assigned Athersys an industry rank of 91 out of 256 based on the ratings given to related companies.
Several research analysts have commented on ATHX shares. BidaskClub downgraded shares of Athersys from a “hold” rating to a “sell” rating in a research report on Sunday, June 30th. Dawson James started coverage on shares of Athersys in a research report on Monday, August 26th. They set a “buy” rating and a $11.00 price objective for the company. Finally, ValuEngine upgraded shares of Athersys from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st.
Shares of ATHX stock traded up $0.02 during trading on Friday, hitting $1.49. The company had a trading volume of 2,564 shares, compared to its average volume of 511,925. The stock’s 50-day moving average price is $1.35 and its 200 day moving average price is $1.54. Athersys has a one year low of $1.20 and a one year high of $2.23.
Athersys (NASDAQ:ATHX) last announced its quarterly earnings results on Wednesday, August 7th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.09) by $0.03. Athersys had a negative net margin of 458.03% and a negative return on equity of 106.93%. The business had revenue of $4.26 million for the quarter.
Athersys, Inc, a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions.
Recommended Story: Street Name
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Athersys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athersys and related companies with MarketBeat.com's FREE daily email newsletter.